$42.45
+0.61
(+1.46%)▲
Insights on Ionis Pharmaceuticals, Inc.
Revenue is up for the last 2 quarters, 144.0M → 324.50M (in $), with an average increase of 55.6% per quarter
Netprofit is up for the last 2 quarters, -147.0M → -9.26M (in $), with an average increase of 1487.0% per quarter
In the last 1 year, Novo Nordisk A/s has given 52.6% return, outperforming this stock by 36.0%
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 249.4%
1.32%
Downside
Day's Volatility :1.87%
Upside
0.56%
19.15%
Downside
52 Weeks Volatility :36.96%
Upside
22.02%
Period | Ionis Pharmaceuticals, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -17.31% | 2.0% | 0.0% |
6 Months | -9.59% | 11.7% | 0.0% |
1 Year | 17.13% | 5.8% | 1.3% |
3 Years | -4.1% | 14.2% | -22.1% |
Market Capitalization | 6.0B |
Book Value | $2.68 |
Earnings Per Share (EPS) | -2.56 |
PEG Ratio | 25.7 |
Wall Street Target Price | 55.95 |
Profit Margin | -46.5% |
Operating Margin TTM | 4.79% |
Return On Assets TTM | -7.51% |
Return On Equity TTM | -76.34% |
Revenue TTM | 787.6M |
Revenue Per Share TTM | 5.5 |
Quarterly Revenue Growth YOY | 113.6% |
Gross Profit TTM | -257.9M |
EBITDA | -319.2M |
Diluted Eps TTM | -2.56 |
Quarterly Earnings Growth YOY | -0.44 |
EPS Estimate Current Year | -3.97 |
EPS Estimate Next Year | -3.24 |
EPS Estimate Current Quarter | -0.83 |
EPS Estimate Next Quarter | -1.01 |
What analysts predicted
Upside of 31.8%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 599.7M | ↑ 18.12% |
Net Income | 273.7M | ↓ 4685.28% |
Net Profit Margin | 45.65% | ↑ 46.83% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↑ 87.27% |
Net Income | 294.0M | ↑ 7.4% |
Net Profit Margin | 26.18% | ↓ 19.47% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 729.0M | ↓ 35.08% |
Net Income | -487.0M | ↓ 265.65% |
Net Profit Margin | -66.8% | ↓ 92.98% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 810.0M | ↑ 11.11% |
Net Income | -29.0M | ↓ 94.05% |
Net Profit Margin | -3.58% | ↑ 63.22% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 587.0M | ↓ 27.53% |
Net Income | -270.0M | ↑ 831.03% |
Net Profit Margin | -46.0% | ↓ 42.42% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 787.6M | ↑ 34.18% |
Net Income | -366.3M | ↑ 35.66% |
Net Profit Margin | -46.5% | ↓ 0.5% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 159.8M | ↑ 19.42% |
Net Income | -47.0M | ↓ 55.3% |
Net Profit Margin | -29.41% | ↑ 49.17% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 152.0M | ↓ 4.86% |
Net Income | -52.0M | ↑ 10.66% |
Net Profit Margin | -34.21% | ↓ 4.8% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 131.0M | ↓ 13.82% |
Net Income | -124.0M | ↑ 138.46% |
Net Profit Margin | -94.66% | ↓ 60.45% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 188.0M | ↑ 43.51% |
Net Income | -85.0M | ↓ 31.45% |
Net Profit Margin | -45.21% | ↑ 49.45% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 144.0M | ↓ 23.4% |
Net Income | -147.0M | ↑ 72.94% |
Net Profit Margin | -102.08% | ↓ 56.87% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 324.5M | ↑ 125.35% |
Net Income | -9.3M | ↓ 93.7% |
Net Profit Margin | -2.85% | ↑ 99.23% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 2.7B | ↑ 101.8% |
Total Liabilities | 1.5B | ↑ 63.91% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 3.2B | ↑ 21.19% |
Total Liabilities | 1.5B | ↑ 4.55% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 2.4B | ↓ 26.07% |
Total Liabilities | 1.5B | ↓ 0.06% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.6B | ↑ 9.29% |
Total Liabilities | 1.8B | ↑ 18.94% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.5B | ↓ 2.99% |
Total Liabilities | 2.0B | ↑ 6.58% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 3.0B | ↑ 18.0% |
Total Liabilities | 2.6B | ↑ 32.76% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.4B | ↓ 1.39% |
Total Liabilities | 1.8B | ↓ 0.21% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.5B | ↑ 4.63% |
Total Liabilities | 2.0B | ↑ 7.3% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.9B | ↑ 13.85% |
Total Liabilities | 2.4B | ↑ 22.28% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.0B | ↑ 2.98% |
Total Liabilities | 2.5B | ↑ 6.05% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.9B | ↓ 1.25% |
Total Liabilities | 2.6B | ↑ 2.99% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.0B | ↑ 1.91% |
Total Liabilities | 2.6B | ↓ 0.6% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 602.9M | ↑ 246.19% |
Investing Cash Flow | -929.6M | ↑ 159.44% |
Financing Cash Flow | 475.9M | ↑ 107.72% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 345.7M | ↓ 42.66% |
Investing Cash Flow | -41.3M | ↓ 95.56% |
Financing Cash Flow | 100.0M | ↓ 78.98% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 35.9M | ↓ 89.62% |
Investing Cash Flow | 274.5M | ↓ 765.01% |
Financing Cash Flow | -596.6M | ↓ 696.48% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 30.8M | ↓ 14.19% |
Investing Cash Flow | 194.9M | ↓ 28.99% |
Financing Cash Flow | 245.9M | ↓ 141.22% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -274.4M | ↓ 990.84% |
Investing Cash Flow | -262.6M | ↓ 234.75% |
Financing Cash Flow | -55.3M | ↓ 122.48% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -24.4M | ↑ 35.0% |
Investing Cash Flow | -183.9M | ↑ 5466.89% |
Financing Cash Flow | 1.8M | ↑ 50.95% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -200.2M | ↑ 719.5% |
Investing Cash Flow | 212.1M | ↓ 215.34% |
Financing Cash Flow | -51.0M | ↓ 2881.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -134.0M | ↓ 33.07% |
Investing Cash Flow | -325.6M | ↓ 253.5% |
Financing Cash Flow | 492.1M | ↓ 1064.52% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -97.4M | ↓ 27.34% |
Investing Cash Flow | 69.5M | ↓ 121.35% |
Financing Cash Flow | 143.5M | ↓ 70.83% |
Sell
Neutral
Buy
Ionis Pharmaceuticals, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Ionis Pharmaceuticals, Inc. | -4.71% | -9.59% | 17.13% | -4.1% | -42.94% |
Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
Vertex Pharmaceuticals Incorporated | -2.67% | 9.62% | 21.65% | 86.62% | 134.62% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Ionis Pharmaceuticals, Inc. | 524.14 | NA | 25.7 | -3.97 | -0.76 | -0.08 | NA | 2.68 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Ionis Pharmaceuticals, Inc. | Buy | $6.0B | -42.94% | 524.14 | -46.5% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 134.62% | 28.81 | 36.68% |
FMR Inc
Vanguard Group Inc
T. Rowe Price Investment Management,Inc.
BlackRock Inc
Bellevue Group AG
ClearBridge Advisors, LLC
ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.
Organization | Ionis Pharmaceuticals, Inc. |
Employees | 927 |
CEO | Dr. Brett P. Monia Ph.D. |
Industry | Health Technology |
Dnp Select Income Closed Fund
$42.45
+1.46%
Masonite International Corp
$42.45
+1.46%
Zillow Group, Inc. - Class C Shares
$42.45
+1.46%
Edgio Inc.
$42.45
+1.46%
Papa John's International Inc.
$42.45
+1.46%
Jpmorgan Betabuilders Europe Etf
$42.45
+1.46%
Marqeta, Inc.
$42.45
+1.46%
Endeavor Group Holdings, Inc.
$42.45
+1.46%
Global X Nasdaq 100 Covered Call Etf
$42.45
+1.46%